Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with ImatinibLaura Cesini, Roberto Latagliata, Fulvio Massaro et al.|Oncology Research and Treatment|2019Cited by 9
Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?Roberto Latagliata, Robin Foà, Massimo Breccia et al.|European Journal Of Haematology|2018Cited by 6
Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?Daniela De Benedittis, Roberto Latagliata, Massimo Breccia et al.|Blood|2018Cited by 0
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center CohortSofia Chiatamone Ricci, Antonietta Ferretti, Maria Antonietta Arleo et al.|Blood|2018Cited by 0